Human Oncology & Pathogenesis Program
The Jedd Wolchok Lab
Research

Professor
The overall goals of my laboratory efforts are to develop and implement new ways to use the immune system to treat cancer.
Some of our ongoing projects include:
- Investigation of the GITR pathway as it relates to regulatory and effector T cells.
- Use of OX40 agonists alone and in combination with chemotherapy.
- Exploration of the role of myeloid derived suppressor cells in tumor immunity.
- Studying of the mechanisms underlying coordinated regulation of myeloid cells and IDO in the tumor environment and their therapeutic relevance.
- Role of CD47 in T cell signaling.
- Developing optimal cancer vaccine strategies in pre-clinical mouse models.
- Role of exercise in immune checkpoint blockade.
We are also closely aligned with the Ludwig Center for Cancer Immunity and work closely with that group to monitor immune responses in patients receiving experimental immunotherapy treatments.

Featured News
Publications
People

Jedd D. Wolchok, MD, PhD, FASCO
Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program
Professor
- Physician-scientist Jedd Wolchok investigates novel approaches for cancer immunotherapy and mechanisms of tumor cell–immune cell interactions. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials.
- Princeton University, Princeton, NJ BA
- New York University, New York, NY MS
- New York University, New York, NY PhD
- New York University, New York, NY MD
- View physician profile
- Physician profile
Members





- PhD in Biochemistry, University of São Paulo (USP), Brazil

- PhD in Immunology, McGill University, Montréal, Canada


- Universite Paris VI
- Universite Paris XI
- 646-888-2322
- Lab Phone

- 646-888-2120
- Office Phone
- 646-888-2581
- Lab Phone






- 646-888-2120
- Office Phone
- 646-888-2585
- Lab Phone




Lab Head

Attending Biologist

Research Lab Manager

Senior Research Scientist

Research Associate

PICI Bridge Scholar

Research Associate

Research Associate

Research Associate

Research Fellow

Research Fellow

Research Fellow

Bioinformatics Technician

Senior Research Assistant

Senior Research Assistant

Senior Research Technician

Senior Research Technician

Research Technician

Research Technician

Research Technician

PhD Graduate Student

PhD Graduate Student

Assistant Attending Physician

Research Technician

Assistant Member

Research Technician

Assistant Attending Physician

Assistant Attending, Department of Medicine

Medical Oncologist

Neuro-Oncologist

Medical Oncologist

Hematologic Oncologist

Medical Oncology Fellow

Medical Oncology Fellow

Medical Oncology Fellow

Research Associate

Research Fellow

Project Coordinator

Research Technician

Graduate Student






Lab Alumni
Immunotherapy Program Manager

Senior Research Scientist

Research Fellow

Research Fellow

Graduate Student

Graduate Student
Research Technician

Senior Research Assistant

Research Technician

Research Technician

Research Technician

Research Technician
Research Technician

Research Technician

Research Technician

Medical Oncologist
Research Laboratory Manager
Assistant Member
Research Fellow
Visiting Investigator
Administrative Assistant

Fulbright Scholar
Research Assistant
Research Technician
Senior Research Technician
Research Assistant
Senior Research Technician
Senior Research Technician

Graduate Research Assistant


Research Fellow

Research Technician

Research Fellow

Research Assistant

Bioinformatics Engineer IV

Research Technician

Visiting Investigator


Research Technician

Research Technician
Lab Affilations
Achievements
- The use of immunomodulatory antibodies, specifically antibodies which interfere with the CTLA-4 co-inhibitory pathway has been studied in over a dozen clinical trials. Dr. Wolchok led a phase III study of ipilimumab plus dacarbazine in patients with previously untreated metastatic melanoma. Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (Wolchok et al, NEJM 30;364(26):2517-26, 2011)
Get in Touch
-
Clinical Office
-
Lab Phone